306 results
Primary• To evaluate the progression free survival (PFS), based on independent radiologic review (IRR), of ASP8273 compared to erlotinib or gefitinib in patients with locally advanced, metastatic or unresectable stage IIIB/IV adenocarcinoma non-…
4.1 Primary• To estimate the Sensitivity and False Positive rate of OTL38 for malignancy detection during Near Infrared Imaging (NIR).• To assess the safety and tolerability of single intravenous doses of OTL384.2 Secondary• To assess the safety of…
Primary aim: Frequency of identifying CTCs and their numbers in apheresis product before and after (during) treatment.Secondary aim: Prediction of response to therapy in different stages of NSCLC patient groups with the change in CTC numbers.
Primary:Cohort 1: To estimate the ORR when a dose of105 mg/m2 LY2606368 every 14 days isadministered to patients with ED-SCLC that haveplatinum-sensitive disease* Cohort 2: To estimate the ORR when a dose of105 mg/m2 LY2606368 every 14 days…
In this study we want to determine the erlotinib concentrations in blood after administration of erlotinib with water or whole milk with and without an antacid .
To assess safety and tolerability of the combination of SBRT and combined CTLA-4/PD-L1 inhibition. In addition immune modulatory effect of the combination of an ablative dose of radiotherapy to the primary tumor and response to durvalumab/…
To determine the safety and tolerability of L19-IL2 combined with SABR.
The primary objective is to assess the impact of hyperhydration on pemetrexed pharmacokinetics. The secondary objective is to compare the performance of different renal function algorithms to predict pemetrexed pharmacokinetics.
To compare tumor [11C]erlotinib pharmacokinetics in NSCLC patients with and without erlotinib therapy. Also, to assess the relationship of venous sampling versus arterial, of tumor [11C]erlotinib uptake and blood flow with and without therapy, and…
This randomized, open label phase III trial will be performed in patients with squamous carcinoma of the lung. The objectives of the trial are to compare the efficacy of afatinib with erlotinib as maintenance and second-line treatment for this group…
The aim of the study is to create and optimize a DWI MRI scan protocol to assess thymic masses.
The objective of this study proposal is to investigate whether use of biomarkers (intracellular pemetrexed levels and/or geneticloci) for response and toxicity to pemetrexed improves the effectiveness of therapy and cost-effectiveness ratio. This…
Trial hypothesisAdding the use of Caphosol® (rinsing and swallowing four times a day) to the standard of care for esophagitis/mucositis, reduces the incidence, onset, duration and severity of esophagitis in (N)SCLC patients, comparing to the…
The goal of this study is to investigate the feasibility of the integration of an EMTS in a standard clinical EUS setting.
The primary objective of this study is to estimate the best objective response rates (ORR; complete response [CR] + partial response [PR]) associated with gemcitabine-cisplatin plus necitumumab in chemotherapy-naïve patients with Stage IV squamous…
To study the effect of surgery and SABR on both immunostimulatory (with primary endpoint CD8 positive cells)and immunosuppressive cells in peripheral blood in patients with early stage non-small cell lung cancer who are treated with either modality.
Primary objective is to analyse whether transnasal videolaryngoscopy in outpatient practice is more accurate in determination of the extend of the affected mucosa of laryngopharyngeal tumours compared to direct laryngoscopy under general anaesthesia…
Primary objective: to define the maximal tolerated dose (MTD) of Olaparib in combination with high dose radiotherapy with and without daily dose cisplatin in locally advanced non-small cell lung carcinoma.
To investigate the dynamics of tumour hypoxia as assessed by 18F-FAZA PET/CT during and after chemoradiotherapy. To investigate the best strategy to deliver a boost dose to the hypoxic tumour areas. This strategy may be either a simultaneous boost (…
To determine the influence of the acidic beverage Coca-Cola, concomitantly taken with erlotinib (with or without a PPI), on erlotinib plasma pharmacokinetics compared to erlotinib concomitantly taken with water in cancer patients.